J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
India · Delayed Price · Currency is INR | Market Cap | 387.31B +50.5% |
| Revenue (ttm) | 41.48B +5.9% |
| Net Income | 7.09B +7.6% |
| EPS | 44.45 +7.0% |
| Shares Out | n/a |
| PE Ratio | 54.59 |
| Forward PE | 43.05 |
| Dividend | 22.00 (0.91%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 4,779,224 |
| Open | 2,506.00 |
| Previous Close | 2,408.90 |
| Day's Range | 2,380.00 - 2,525.50 |
| 52-Week Range | 1,638.50 - 2,525.50 |
| Beta | 0.02 |
| Analysts | Buy |
| Price Target | 2,328.14 (-3.64%) |
| Earnings Date | Aug 7, 2026 |
About NSE:JBCHEPHARM
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powde... [Read more]
Financial Performance
In fiscal year 2026, NSE:JBCHEPHARM's revenue was 41.48 billion, an increase of 5.87% compared to the previous year's 39.18 billion. Earnings were 7.09 billion, an increase of 7.56%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for JBCHEPHARM stock is "Buy." The 12-month stock price target is ₹2,328, which is a decrease of -3.64% from the latest price.
News
JB Chemicals amalgamates with Torrent Pharma as scheme becomes effective
JB Chemicals & Pharmaceuticals Limited has officially amalgamated with Torrent Pharmaceuticals Limited, effective 8th July 2026. This development follows the approval and sanction by the National Comp...
JB Chemicals receives NCLT approval for amalgamation with Torrent Pharmaceuticals
JB Chemicals & Pharmaceuticals has received a certified copy of the National Company Law Tribunal (NCLT) order sanctioning its amalgamation with Torrent Pharmaceuticals. The order, dated 6th July 2026...
JB Chemicals & Pharmaceuticals merger with Torrent Pharmaceuticals sanctioned by NCLT
The National Company Law Tribunal (NCLT) has sanctioned the Scheme of Amalgamation between JB Chemicals & Pharmaceuticals and Torrent Pharmaceuticals. This merger, approved on July 6, 2026, aligns wit...
JB Chemicals executive vice president Bhushan Sachdev resigns
JB Chemicals & Pharmaceuticals has announced the resignation of Mr. Bhushan Sachdev from his position as Executive Vice President of Supply Chain Management. The resignation is effective from the clos...
JB Chemicals & Pharmaceuticals announces 50th AGM via video conference
JB Chemicals & Pharmaceuticals Limited has announced that its 50th Annual General Meeting (AGM) will be held on Wednesday, June 17, 2026, at 3:00 PM (IST). The meeting will be…
JB Chemicals reports 35% of turnover from exports in FY26
JB Chemicals & Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report for the financial year 2025-26, highlighting significant contributions from international mark...
J. B. Chemicals & Pharmaceuticals Transcript: Q4 25/26
Q4 FY26 saw a 5% revenue decline due to operational reset post-acquisition, but gross margin improved to 70% and adjusted EBITDA margin to 27%. India branded business grew 8%, while international and CDMO segments faced shipment and execution challenges. Merger with Torrent Pharma is nearing completion.
J. B. Chemicals & Pharmaceuticals Quarterly report: Q4 2026
J. B. Chemicals & Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 11, 2026.
J. B. Chemicals & Pharmaceuticals Annual report: Q4 2026
J. B. Chemicals & Pharmaceuticals has published its Q4 2026 annual report on May 11, 2026.
JB Chemicals reports Rs 904 crore revenue in Q4 FY26; net profit declines by 30%
JB Chemicals & Pharmaceuticals Ltd announced its financial results for the fourth quarter of FY26, revealing a revenue of ₹904 crore and a net profit after tax of ₹101 crore,…
JB Chemicals calls shareholders' meeting under National Company Law Tribunal order
JB Chemicals & Pharmaceuticals has announced a meeting of its equity shareholders convened pursuant to an order issued by the National Company Law Tribunal (NCLT), Ahmedabad Bench, on March 23,…
Stocks to buy: What's the outlook for Nifty for March 23-27 week? Check list of top stock recommendations
Stock market recommendations: Coal India, and JB Chemicals and Pharmaceuticals stocks that Sudeep Shah, Head - Technical Research and Derivatives, SBI Securities recommends buying for the week startin...
JB Chemicals announces resignation of Sushree Mishra as General Manager
Sushree Mishra has resigned from her position as General Manager-Corporate Strategy, Communication and In-licensing at JB Chemicals & Pharmaceuticals, effective from the close of business on 13 March ...
JB Chemicals announces resignation of Executive Vice President Jason D'souza
JB Chemicals & Pharmaceuticals has announced the resignation of its Executive Vice President, Jason D'souza, effective from the close of business on 6 March 2026. The company disclosed that the…
JB Chemicals announces resignation of three senior executives
JB Chemicals & Pharmaceuticals has announced the resignation of three senior executives, effective early March 2026. Mr. Kunal Khanna, who served as President – Operations, and Mr. Dilip Singh Rathore...
JB Chemicals announces senior management changes with three resignations
JB Chemicals & Pharmaceuticals has announced significant changes in its senior management team. The company confirmed that Mr. Kunal Khanna, who served as President – Operations, and Mr. Dilip Singh…
J. B. Chemicals & Pharmaceuticals Transcript: Q3 25/26
Q3 FY26 saw 11% revenue growth and 22% net profit growth, with gross margins up 200 bps to 69.1%. Domestic and international businesses both outperformed their respective markets, and guidance for margins and growth remains strong for FY26.
J. B. Chemicals & Pharmaceuticals Quarterly report: Q3 2026
J. B. Chemicals & Pharmaceuticals has published its Q3 2026 quarterly earnings report on January 19, 2026.
J. B. Chemicals & Pharmaceuticals Slides: Q3 2026
J. B. Chemicals & Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 19, 2026.
J. B. Chemicals & Pharmaceuticals Transcript: Q2 25/26
Q2 FY 2026 saw 8% revenue growth and 19% net profit growth, with gross margin up to 68.2% and strong performance in the domestic and CDMO segments. Guidance for 12%-14% growth in domestic and CDMO businesses is maintained, with margin outlook reaffirmed.
J. B. Chemicals & Pharmaceuticals Quarterly report: Q2 2026
J. B. Chemicals & Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 12, 2025.
J. B. Chemicals & Pharmaceuticals Slides: Q2 2026
J. B. Chemicals & Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 12, 2025.
Stocks to watch today, Sept 5: Sterlite Tech, JB Chemicals, Bharat Forge, Zydus Lifesciences, Varun Beverages in focus
Indian markets are expected to remain stock-specific on Friday, September 5, 2025, as a series of corporate announcements and strategic developments put several companies in focus. Here are the major ...
J. B. Chemicals & Pharmaceuticals Transcript: Q1 25/26
Q1 FY26 saw 9% revenue growth, 14% net profit rise, and record 30.2% EBITDA margin, with strong domestic and CDMO performance. Torrent Pharma's acquisition and merger plans mark a major strategic shift, while guidance for margins and growth remains robust.
J. B. Chemicals & Pharmaceuticals Quarterly report: Q1 2026
J. B. Chemicals & Pharmaceuticals has published its Q1 2026 quarterly earnings report on July 31, 2025.